Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA

Orthofix Medical Inc.

2025-FY EPS reported -$2.33 revenue$822,312,000

Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.
Full-year 2025 net sales $822.3M (+2.9% reported); pro forma $811.9M (+4.1% constant currency).
FY25 net loss $(92.2)M, improved from $(126.0)M; free cash flow $3.1M (ex-M6 restructuring).
2026 guidance: net sales $850-860M (~5.5% pro forma CC growth); adj. EBITDA $95-98M.
Three-year targets (2026-28): 6.5-7.5% sales CAGR, mid-teens EBITDA margin by 2028, positive FCF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.